Status:
COMPLETED
TUMORAPA 1: Efficacy of Rapamycin in Secondary Prevention of Skin Cancers in Kidney Transplant Recipients
Lead Sponsor:
Hospices Civils de Lyon
Conditions:
Skin Cancer
Kidney Transplantation
Eligibility:
All Genders
18-80 years
Phase:
PHASE3
Brief Summary
In a population of kidney transplant recipients having developed a first squamous cell carcinoma, the aim of the study is to assess the incidence of subsequent skin cancers over 2 years in patients wh...
Eligibility Criteria
Inclusion
- First post-transplant squamous cell carcinoma in a kidney transplant recipient under calcineurin inhibitors
Exclusion
- Other squamous cell carcinomas in the past history
- More than 2 transplantations
- Patients not under calcineurin inhibitors
- Unstable graft function
- Non controlled hyperlipidemia (cholesterol \> 7.8 mmol/l or triglycerides \> 3.95 mmol/l)
- Leucopenia \< 3000/mm3
- Thrombocytopenia \< 100,000/mm3
- Liver dysfunction
- Pregnancy
- Allergy to macrolides
Key Trial Info
Start Date :
April 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2014
Estimated Enrollment :
77 Patients enrolled
Trial Details
Trial ID
NCT00133887
Start Date
April 1 2004
End Date
May 1 2014
Last Update
December 26 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital Edouard Herriot - Service de Dermatologie
Lyon, France, 69003